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Abstract
Alzheimer’s disease (AD) is characterized by two neuropathological hallmarks: senile plaques, which are composed of
amyloid-β (Aβ) peptides, and neurofibrillary tangles, which are composed of hyperphosphorylated tau protein. Aβ
peptides are derived from sequential proteolytic cleavage of the amyloid precursor protein (APP). In this study, we
identified a so far unknown mode of regulation of APP protein synthesis involving the MID1 protein complex: MID1
binds to and regulates the translation of APP mRNA. The underlying mode of action of MID1 involves the mTOR
pathway. Thus, inhibition of the MID1 complex reduces the APP protein level in cultures of primary neurons. Based on
this, we used one compound that we discovered previously to interfere with the MID1 complex, metformin, for in vivo
experiments. Indeed, long-term treatment with metformin decreased APP protein expression levels and consequently
Aβ in an AD mouse model. Importantly, we have initiated the metformin treatment late in life, at a time-point where
mice were in an already progressed state of the disease, and could observe an improved behavioral phenotype. These
findings together with our previous observation, showing that inhibition of the MID1 complex by metformin also
decreases tau phosphorylation, make the MID1 complex a particularly interesting drug target for treating AD.
Introduction
Alzheimer’s disease (AD), the most common form of
dementia in the elderly, is characterized by two neuro-
pathological hallmarks: senile plaques, which are com-
posed of Aβ peptides, and neurofibrillary tangles, which
are composed of hyperphosphorylated tau protein. The
disease was first described in 1907 by Alois Alzheimer1,
who observed these two pathological hallmarks in
patients’ brains. Aβ peptides are derived from sequential
proteolytic cleavage of the amyloid precursor protein
(APP). While the non-amyloidogenic pathway involves
sequential cleavage of full-length APP by the α-secretases
and γ-secretase, the amyloidogenic pathway causing the
production of Aβ peptides requires the cleavage of full-
length APP by the β-secretase BACE1 and the γ-
secretase2. Multiple lines of evidence suggest that over-
production of Aβ results in neuronal dysfunction and,
finally, in neuronal loss3. The second pathological hall-
mark of AD, neurofibrillary tangles, are mainly composed
of hyperphosphorylated tau protein4,5. Tau is a
microtubule-associated protein that stimulates and
stabilizes microtubule assembly. Upon hyperpho-
sphorylation, tau dissociates from microtubules, resulting
in microtubule destabilization and neuronal death. The
main tau phosphatase is protein phosphatase 2A (PP2A),
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which is capable of dephosphorylating tau at AD-relevant
phospho-sites6.
As we have shown previously, the MID1-PP2A protein
complex regulates the phosphorylation of tau7. MID1 acts
as an E3 ubiquitin ligase and promotes the ubiquitin-
dependent degradation of PP2A8. Therefore, MID1 is a
negative regulator of PP2A activity and thus inhibition of
the MID1-PP2A complex is a promising approach to
activate PP2A, and thereby induce its activity towards its
target protein tau. In line with this, we have shown pre-
viously that the anti-diabetic drug metformin is capable of
dephosphorylating tau at AD-relevant phospho-sites by
interfering with the assembly of the MID1-PP2A-
complex7. Upon metformin treatment, the MID1-
dependent degradation of PP2Ac is inhibited, resulting
in increased PP2A activity and dephosphorylation of tau
at AD specific sites7. Besides regulating PP2A activity,
MID1 also regulates the activity of the PP2A opposing
kinase mTOR9. Both enzymes, PP2A and mTOR, play a
crucial role in the regulation of translation initiation by
the eukaryotic initiation factor (eIF) complex. In detail, in
absence of mTOR, a negative regulatory protein complex
containing 4E-BP1 in association with eIF4E binds to the
5′ end of the mRNA and inhibits translation. To activate
translation mTOR phosphorylates 4E-BP1, thereby
releasing its inhibitory action and allowing a hetero-
trimeric complex containing eIF4E, eIF4A, and eIF4G to
assemble at the 5′ end of the mRNA. At the same time,
mTOR also phosphorylates and thereby activates p70 S6
kinase (S6K). S6K in turn phosphorylates and thereby
activates its downstream targets eIF4B and S6. S6 is part
of the small ribosomal subunit (40S). eIF3 is a multi-
subunit protein that recruits 40S to the mRNA. Once
associated with the mRNA, 40S starts scanning towards
the ATG start codon. Upon start codon recognition, the
large ribosomal subunit (60S) binds and, together with
40S, forms the translationally competent ribosome. The
eIF complex is released from the mRNA and translation
starts10. PP2A and mTOR control translation by reg-
ulating the phosphorylation of 4E-BP1 and S6K. MID1
binds to GC-rich mRNAs and recruits its interacting
proteins, including S6K and S611,12. By regulating the
activity of both PP2A and mTOR, MID1 controls the
translation of mRNAs bound to the MID1 complex11–14.
In this study we asked if MID1, besides its regulatory
action on phospho-tau, could also affect APP. We show
here a so far unknown connection between MID1 and
APP: MID1 binds to the APP mRNA and regulates its
translation. The underlying mode of action of MID1
involves the mTOR-dependent translation initiation
pathway. Furthermore, we used metformin, a compound
that we had shown previously to interfere with the MID1
complex and inactivate translation of MID1-target
mRNAs7,14,15, for a chronic treatment of an AD mouse
model at a progressed state of disease. Our data show that
metformin treatment decreases the protein levels of APP
and consequently Aβ. This together with our previous
observation that disassembly of the MID1 protein com-
plex by metformin also decreases tau-phosphorylation7,
makes the MID1 protein complex a particularly interest-
ing drug target for treating AD.
Results
Translation of APP is regulated by MID1
To investigate if the APP mRNA is regulated by the
MID1-PP2A complex, we first tested if MID1 is able to
bind to APP mRNA. For this we performed RNA-
immunoprecipitations. Primary cortical neurons of wild-
type mice were transfected with FLAG-MID1. After UV-
crosslinking FLAG-MID1 was purified and MID1-bound
mRNAs were isolated from the immunoprecipitates. As
negative control an immunoprecipitation using unspecific
Fig. 1 APP is a MID1 target mRNA. a RNA immunoprecipitation. Primary neurons were transfected with MID1-FLAG. Afterwards MID1-mRNPs were
purified by immunoprecipitation (IP FLAG) and MID1-bound mRNAs were analyzed for the presence of APP mRNA using RT-PCR. Unspecific IgG
beads (IgG) were used as negative control. 5 µl of the PCR product were analyzed on a 1% agarose gel. b Inhibition of the MID1 complex reduces APP
protein level. Primary cortical neurons were treated with a peptide that mimics the MID1-α4 binding site and thus outcompetes MID1 (GSK’364A). A
mutant peptide was used as negative control (GSK’365A). APP protein levels were analyzed on western blots using APP-specific antibodies. β-actin
was detected as loading control. A representative blot of n = 3 is shown. Graphs show quantification of western blots, mean values ± SEM. *p < 0.05.
c Relative APP mRNA expression was measured in cells treated as in b by means of real-time PCR. Columns represent mean values ± SEM. n = 3. APP
amyloid precursor protein
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IgGs was performed. RT-PCRs clearly showed the pre-
sence of APP mRNA in the MID1-immunoprecipitates
(Fig. 1a).
In previous studies we showed that binding of the
MID1-complex to its target mRNAs induces protein
translation from the respective mRNA12,15,16. Therefore,
we asked if the observed binding between APP mRNA
and MID1 leads to an induction of APP translation. To
test this we performed an experiment in primary cortical
neurons with a peptide that mimics the binding sequence
between MID1 and the α4-PP2A complex and therefore
specifically outcompetes MID1. Depletion of MID1 led to
a significant reduction of APP protein as shown on a
western blot (Fig. 1b). Of note, the mRNA level of APP
did not change significantly (Fig. 1c), which is in line with
an inhibition at the protein synthesis level.
MID1 regulates APP translation by interacting with the
mTOR-dependent translation initiation pathway
As we have shown previously, the MID1-complex reg-
ulates translation in concert with mTOR. To identify at
which exact step of the mTOR-dependent translation
initiation MID1 functions, we analyzed proteins that bind
to MID1. For this we performed an immunoprecipitation
of FLAG-MID1 and analyzed all MID1-bound proteins by
mass spectrometry. As expected, we detected several
members of the mTOR-translation initiation cascade
(Fig. 2a and Table 1), several of which we validated on a
western blot of FLAG-MID1-immunoprecipitates using
specific antibodies (Fig. 2b). Interestingly, all MID1-
bound proteins identified here were proteins of the
mTOR-dependent translation pathway that act down-
stream of mTOR as well as S6K and 4E-BP, suggesting
that MID1 regulates the mTOR-dependent translation by
acting on either the eIFs or the ribosome. Thus, in a
second set of experiments we added EDTA during the co-
immunoprecipitation. EDTA dissociates ribosomal parti-
cles17. While binding of most of the identified proteins to
MID1 was abolished by the treatment, RPLP0, a member
of the large subunit of the ribosome remained attached to
MID1 (Fig. 2c). Since all of the proteins identified by mass
spectrometry bind RNA in general, their presence in the
MID1-immunoprecipitate may be explained by RNA-
mediated indirect binding rather than by direct protein-
protein interaction. To test which of the identified pro-
teins bind to MID1 independent of RNA, we performed
co-immunoprecipitation experiments in the presence or
absence of RNase. Binding of the identified eIF proteins to
MID1 was abolished by RNase treatment, while RPLP0,
RPL5, and RPS3 remained attached to MID1 (Fig. 2d).
These data suggest that MID1 directly binds to the ribo-
some to stimulate mTOR-dependent translation. In line
with a MID1-mTOR dependent translation of APP,
application of an mTOR inhibitor reduced APP
translation both in an in vitro translation assay (Fig. 2e) as
well as in primary neurons (Fig. 2f).
Metformin reduces APP protein and APP cleavage
products
To target MID1 we decided to use metformin, a com-
pound that we had shown previously to interfere with the
MID1 complex and inactivate translation of MID1-target
mRNAs7,14,15. In line with what we have observed for
other MID1-target mRNAs, metformin treatment of pri-
mary cortical neurons also led to a reduction of APP
protein in a dose-dependent manner (Fig. 3a).
Finally, to investigate this effect in vivo, we chronically
treated transgenic APP/PS1 mice with 5 g/l metformin in
the drinking water for 8 months. In line with our data
from primary neurons, full-length APP protein was sig-
nificantly reduced in metformin treated mice (Fig. 4a),
while APP mRNA levels were not significantly changed
after metformin treatment (Fig. 4b). Together, these data
suggest that the APP protein level was decreased in vivo
on the translational level, which can be explained by
inhibition of the MID1 complex. In line with an mTOR-
MID1-PP2A-dependent down-regulation of APP in these
mice, the phosphorylation of S6 was significantly reduced
in brain lysates of these mice, as determined by western
blots (Fig. 4c).
A reduction of APP should lead to a reduced Aβ plaque
burden in the treated animals. To quantify this we first
measured levels of Aβ on dot blots, showing that Aβ levels
were significantly decreased in metformin treated animals
(Fig. 5a). Second, in an ELISA measuring the levels of
Aβ40 and Aβ42, a significant decrease of Aβ peptides was
observed in both female and male mice (Fig. 5b). Of note,
there was also a significant difference in Aβ levels between
female and male mice. To investigate the Aβ plaque
burden in the hippocampus, we performed Thioflavin-S
stainings. In line with dot blot and ELISA experiments,
thioflavin staining showed less aggregates in metformin
treated animals (Fig. 5c). To test if metformin affects
learning and memory, APP/PS1 mice that were treated
with metformin were examined in behavioral tests. A
significantly improved performance in the Morris water
maze was observed in animals that were treated with
metformin (Fig. 5d).
Besides regulating translation, mTOR is also a known
regulator of autophagy. Therefore, in our in vivo set-up
we cannot rule out that the observed reduction of Aβ
could be at least partially due to increased clearance via
autophagy. To address this, we analyzed the degradation
of Aβ in SH-EP cells containing TAMRA-Aβ42 aggre-
gates. Clearly, no increased degradation of Aβ was
detectable in these cells, suggesting that metformin
treatment does not induce autophageal degradation of Aβ
(Fig. 6).
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Fig. 2 MID1 is connected to the mTOR-dependent translation initiation pathway. a Identification of the MID1-interactome. MID1-FLAG was
expressed in HEK293T cells and MID1-complexes were purified by immunoprecipitation. MID1-binding proteins were identified by mass
spectrometry. The mTOR-dependent translation initiation pathway is shown and the number of proteins identified belonging either to the eukaryotic
translation initiation factor complex (eIF complex) or the ribosome are indicated. b Validation of the mass spectrometry results shown in a and
Table 1. MID1-FLAG was expressed in HEK293T cells and MID1-complexes were purified by immunoprecipitation (IP FLAG). As negative control,
unspecific IgG agarose beads were used (IgG). Immunoprecipitates were analyzed on western blots using specific antibodies to detect MID1-FLAG,
eIF3A, eIF4G, RPLP0, RPL5, RPS3. c Effect of ribosome disassembly on the composition of the MID1-complex. MID1-FLAG was expressed in
HEK293T cells and immunopurified (IP FLAG) in the presence or absence of high concentrations of EDTA. Immunoprecipitates were analyzed on
western blots using specific antibodies for MID1-FLAG, eIF3A, RPLP0, RPL5, RPS3. d To analyze the MID1-complex composition and its dependency on
RNA, MID1-FLAG was expressed in HEK293T cells and immunopurified (IP FLAG) in the presence or absence of RNAse. As negative control, unspecific
IgG agarose beads were used (IgG). Immunoprecipitates were analyzed on western blots using specific antibodies for MID1-FLAG, eIF3A, eIF4G,
RPLP0, RPL5, RPS3. e, f mTOR regulates translation of APP. e In vitro translation of in vitro transcribed APP-mRNA tagged to luciferase in the presence
or absence of the mTOR-inhibitor temsirolimus. The level of translated luciferase reporter was measured in a luciferase assay. Columns represent
mean values ± SEM. n = 3. *p < 0.01. f Primary neurons were treated with the mTOR-inhibitor temsirolimus. Protein extracts were analyzed on western
blots, detecting APP and β-actin as loading control. Graph shows quantification of western blots, mean values ± SEM. n = 3. *p < 0.01. APP amyloid
precursor protein
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Table 1 Statistical analysis of proteins identified mass spectrometry analysis of MID1 immunoprecipitates
Protein name Gene ID Log2 ratio P-value
ATP-binding cassette sub-family D member 3 ABCD3 2.75E+01 2.04E-03
ATP-binding cassette sub-family F member 2 ABCF2 2.88E+01 5.96E-04
Apoptotic chromatin condensation inducer in the nucleus ACIN1 2.72E+01 1.39E-02
Aldehyde dehydrogenase X, mitochondrial ALDH1B1 2.62E+01 3.61E-04
Mitochondrial 10-formyltetrahydrofolate dehydrogenase ALDH1L2 2.66E+01 1.97E-02
THO complex subunit 4 ALYREF 2.99E+01 7.55E-04
Serine/threonine-protein phosphatase 6 reg. ankyrin repeat subunit A ANKRD28 2.63E+01 1.85E-02
Coatomer subunit delta ARCN1 2.65E+01 2.36E-02
Activating signal cointegrator 1 complex subunit 3 ASCC3 2.59E+01 7.96E-03
ATPase family AAA domain-containing protein 3A ATAD3A 1.77E+00 3.98E-02
Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1 2.72E+01 4.39E-04
Ribosome biogenesis protein BMS1 homolog BMS1 2.90E+01 8.92E-03
Ribosome biogenesis protein BRX1 homolog BRIX1 2.68E+01 1.41E-02
Caprin-1 CAPRIN1 2.80E+01 5.88E-03
Coiled-coil domain-containing protein 124 CCDC124 2.94E+01 1.91E-04
T-complex protein 1 subunit gamma CCT3 2.63E+01 4.86E-02
T-complex protein 1 subunit epsilon CCT5 2.64E+01 1.42E-03
Cell division cycle 5-like protein CDC5L 3.04E+01 3.51E-03
Centrosomal protein of 170 kDa CEP170 2.71E+01 2.53E-03
Chromatin target of PRMT1 protein CHTOP 2.81E+01 3.45E-02
CLIP-associating protein 2 CLASP2 2.74E+01 4.83E-03
Methylosome subunit pICln CLNS1A 2.97E+01 2.16E-03
Coatomer subunit gamma-2 COPG2 2.59E+01 2.98E-04
Coronin-1C CORO1C 3.03E+01 2.00E-02
Cleavage and polyadenylation specificity factor subunit 6 CPSF6 2.93E+01 4.13E-03
Cleavage and polyadenylation specificity factor subunit 7 CPSF7 2.73E+01 2.20E-03
Probable ATP-dependent RNA helicase DDX17 DDX17 3.22E+01 1.28E-02
Probable ATP-dependent RNA helicase DDX20 DDX20 2.73E+01 2.81E-02
Nucleolar RNA helicase 2 DDX21 3.01E+01 8.42E-03
Probable ATP-dependent RNA helicase DDX23 DDX23 2.93E+01 4.58E-03
ATP-dependent RNA helicase DDX3X DDX3X 2.66E+01 5.42E-04
Probable ATP-dependent RNA helicase DDX41 DDX41 2.73E+01 4.88E-03
Probable ATP-dependent RNA helicase DDX5 DDX5 2.97E+01 1.38E-02
ATP-dependent RNA helicase DDX50 DDX50 2.65E+01 5.75E-03
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 DHX15 2.76E+01 6.67E-03
Putative ATP-dependent RNA helicase DHX30 DHX30 2.99E+01 1.03E-02
ATP-dependent RNA helicase A DHX9 7.63E+00 4.50E-03
Elongation factor 2 EEF2 4.68E+00 8.14E-03
116 kDa U5 small nuclear ribonucleoprotein component EFTUD2 3.04E+01 6.54E-03
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Table 1 continued
Protein name Gene ID Log2 ratio P-value
Eukaryotic translation initiation factor 3 subunit A EIF3A 3.34E+01 2.89E-04
Eukaryotic translation initiation factor 3 subunit B EIF3B 3.19E+01 6.22E-03
Eukaryotic translation initiation factor 3 subunit C EIF3C 3.23E+01 1.43E-03
Eukaryotic translation initiation factor 3 subunit D EIF3D 3.01E+01 1.72E-03
Eukaryotic translation initiation factor 3 subunit E EIF3E 3.15E+01 2.60E-03
Eukaryotic translation initiation factor 3 subunit F EIF3F 3.08E+01 9.00E-03
Eukaryotic translation initiation factor 3 subunit G EIF3G 2.99E+01 1.64E-04
Eukaryotic translation initiation factor 3 subunit I EIF3I 3.07E+01 4.95E-03
Eukaryotic translation initiation factor 3 subunit J EIF3J 2.75E+01 2.97E-04
Eukaryotic translation initiation factor 3 subunit K EIF3K 2.75E+01 4.35E-02
Eukaryotic translation initiation factor 3 subunit L EIF3L 3.20E+01 1.62E-03
Eukaryotic translation initiation factor 3 subunit M EIF3M 3.06E+01 2.52E-02
Eukaryotic translation initiation factor 3 subunit H EIF3S3 2.98E+01 4.34E-03
Eukaryotic initiation factor 4A-I EIF4A1 2.82E+01 1.28E-02
Eukaryotic initiation factor 4A-III EIF4A3 2.66E+01 2.37E-02
Eukaryotic translation initiation factor 4B EIF4B 3.07E+01 1.05E-02
Eukaryotic translation initiation factor 6 EIF6 2.71E+01 1.74E-02
Emerin EMD 2.73E+01 1.99E-02
Erlin-2 ERLIN2 2.81E+01 7.54E-03
Exosome component 10 EXOSC10 2.76E+01 3.45E-03
Exosome complex component RRP45 EXOSC9 2.59E+01 2.53E-02
Constitutive coactivator of PPAR-gamma-like protein 1 FAM120A 2.74E+01 1.36E-02
Phenylalanine--tRNA ligase alpha subunit FARSA 2.78E+01 7.54E-03
Phenylalanine--tRNA ligase beta subunit FARSB 2.78E+01 1.17E-02
40S ribosomal protein S30 FAU 2.85E+01 2.31E-03
Protein furry homolog-like FRYL 3.02E+01 2.54E-02
Gem-associated protein 4 GEMIN4 2.71E+01 2.53E-03
Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 3.25E+01 3.47E-04
Nucleolar GTP-binding protein 2 GNL2 2.75E+01 7.11E-03
Guanine nucleotide-binding protein-like 3 GNL3 2.69E+01 4.03E-04
Golgin subfamily A member 3 GOLGA3 2.93E+01 3.96E-03
General transcription factor 3C polypeptide 2 GTF3C2 2.75E+01 3.97E-03
General transcription factor 3C polypeptide 3 GTF3C3 2.57E+01 3.56E-02
General transcription factor 3C polypeptide 4 GTF3C4 2.70E+01 2.46E-03
Nucleolar GTP-binding protein 1 GTPBP4 2.87E+01 1.26E-02
Histone H2B HIST1H2BN 2.99E+01 1.62E-02
Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC 3.08E+01 3.22E-04
Heterogeneous nuclear ribonucleoprotein D0 HNRNPD 2.60E+01 2.60E-02
Heterogeneous nuclear ribonucleoprotein F HNRNPF 2.74E+01 4.67E-03
Heterogeneous nuclear ribonucleoprotein K HNRNPK 2.96E+01 9.43E-04
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Table 1 continued
Protein name Gene ID Log2 ratio P-value
Heterogeneous nuclear ribonucleoprotein M HNRNPM 6.56E+00 1.98E-02
Heterogeneous nuclear ribonucleoprotein R HNRNPR 2.99E+01 4.29E-03
Heterogeneous nuclear ribonucleoprotein U HNRNPU 3.23E+01 2.34E-03
Isoleucine--tRNA ligase, cytoplasmic IARS 2.72E+01 3.12E-03
Insulin-like growth factor 2 mRNA-binding protein 1 IGF2BP1 3.18E+01 1.09E-03
Insulin-like growth factor 2 mRNA-binding protein 3 IGF2BP3 2.81E+01 1.22E-02
Interleukin enhancer-binding factor 2 ILF2 3.10E+01 1.08E-02
Interleukin enhancer-binding factor 3 ILF3 3.27E+01 2.99E-03
Importin-8 IPO8 2.74E+01 1.30E-02
Insulin receptor substrate 4 IRS4 1.33E+00 3.38E-03
Influenza virus NS1A-binding protein IVNS1ABP 3.33E+01 3.05E-03
Tyrosine-protein kinase JAK1 JAK1 2.88E+01 4.64E-03
BTB/POZ domain-containing protein KCTD17 KCTD17 2.96E+01 1.23E-02
BTB/POZ domain-containing protein KCTD5 KCTD5 2.96E+01 3.67E-04
Kinesin-like protein KIF11 KIF11 1.48E+00 1.25E-03
La-related protein 1 LARP1 3.17E+01 9.37E-04
La-related protein 4 LARP4 2.86E+01 7.22E-03
La-related protein 4B LARP4B 2.65E+01 8.21E-03
LIM domain and actin-binding protein 1 LIMA1 2.98E+01 7.34E-03
Leucine-rich PPR motif-containing protein, mitochondrial LRPPRC 2.63E+01 8.82E-03
Putative RNA-binding protein Luc7-like 2 LUC7L2 3.00E+01 3.39E-03
Luc7-like protein 3 LUC7L3 2.81E+01 5.20E-03
Microtubule-associated protein 1B MAP1B 3.01E+01 3.76E-03
Serine/threonine-protein kinase MARK2 MARK2 2.60E+01 3.76E-03
Methionine--tRNA ligase, cytoplasmic MARS 2.62E+01 1.62E-03
Matrin-3 MATR3 2.87E+01 1.32E-03
DNA replication licensing factor MCM7 MCM7 2.83E+01 8.19E-03
E3 ubiquitin-protein ligase Midline-1 MID1 3.76E+01 3.26E-04
Putative helicase MOV-10 MOV10 2.77E+01 2.49E-02
28S ribosomal protein S17, mitochondrial MRPS17 2.91E+01 6.96E-03
28S ribosomal protein S22, mitochondrial MRPS22 2.74E+01 4.69E-03
28S ribosomal protein S25, mitochondrial MRPS25 2.71E+01 1.14E-02
28S ribosomal protein S27, mitochondrial MRPS27 2.64E+01 3.48E-02
Protein LYRIC MTDH 2.72E+01 1.03E-02
Myb-binding protein 1A MYBBP1A 2.90E+01 1.44E-04
Myosin-10 MYH10 1.13E+00 2.28E-02
Myosin-9 MYH9 2.92E+01 4.78E-03
Unconventional myosin-Ib MYO1B 2.71E+01 2.88E-02
Nicotinamide phosphoribosyltransferase NAMPT 2.75E+01 8.55E-03
Nucleosome assembly protein 1-like 1 NAP1L1 2.57E+01 7.18E-03
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Table 1 continued
Protein name Gene ID Log2 ratio P-value
Nuclear cap-binding protein subunit 1 NCBP1 2.81E+01 4.89E-04
Nucleolin NCL 2.86E+01 6.74E-03
Nucleolar complex protein 4 homolog NOC4L 2.80E+01 8.27E-03
Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase NOP2 2.62E+01 5.08E-03
Cleavage and polyadenylation specificity factor subunit 5 NUDT21 2.96E+01 6.21E-04
OTU domain-containing protein 4 OTUD4 2.74E+01 1.45E-03
Prolyl 4-hydroxylase subunit alpha-1 P4HA1 2.79E+01 4.44E-03
Proliferation-associated protein 2G4 PA2G4 3.08E+01 7.55E-03
Polyadenylate-binding protein 1 PABPC1 3.23E+01 2.17E-03
Polyadenylate-binding protein 4 PABPC4 3.22E+01 2.78E-03
Programmed cell death protein 4 PDCD4 2.94E+01 8.37E-03
Proline-, glutamic acid- and leucine-rich protein 1 PELP1 2.66E+01 9.09E-03
Serine/threonine-protein phosphatase PGAM5, mitochondrial PGAM5 2.86E+01 3.52E-03
Protein arginine N-methyltransferase 5 PRMT5 3.54E+01 6.16E-04
Pre-mRNA-processing factor 19 PRPF19 3.02E+01 3.67E-03
U4/U6 small nuclear ribonucleoprotein Prp3 PRPF3 2.70E+01 1.69E-02
U4/U6 small nuclear ribonucleoprotein Prp31 PRPF31 2.97E+01 8.19E-04
U4/U6 small nuclear ribonucleoprotein Prp4 PRPF4 2.64E+01 3.83E-03
Pre-mRNA-processing factor 6 PRPF6 2.98E+01 6.12E-03
Pre-mRNA-processing-splicing factor 8 PRPF8 3.11E+01 3.06E-03
Ribose-phosphate pyrophosphokinase 1 PRPS1 5.58E+00 3.60E-03
Ribose-phosphate pyrophosphokinase 2 PRPS2 2.93E+01 1.56E-02
Phosphoribosyl pyrophosphate synthase-associated protein 1 PRPSAP1 3.05E+01 8.50E-03
Phosphoribosyl pyrophosphate synthase-associated protein 2 PRPSAP2 3.25E+01 2.15E-04
Protein PRRC2A PRRC2A 2.85E+01 8.43E-03
Protein PRRC2C PRRC2C 2.97E+01 2.05E-02
26S protease regulatory subunit 4 PSMC1 2.97E+01 5.78E-03
26S protease regulatory subunit 7 PSMC2 3.07E+01 8.06E-04
26S protease regulatory subunit 6A PSMC3 2.89E+01 5.50E-03
26S protease regulatory subunit 6B PSMC4 1.19E+00 1.54E-02
26S protease regulatory subunit 8 PSMC5 4.55E+00 3.71E-04
26S protease regulatory subunit 10B PSMC6 2.84E+01 1.52E-03
26S proteasome non-ATPase regulatory subunit 1 PSMD1 2.97E+01 2.12E-03
26S proteasome non-ATPase regulatory subunit 10 PSMD10 2.85E+01 2.02E-02
26S proteasome non-ATPase regulatory subunit 11 PSMD11 3.02E+01 1.94E-02
26S proteasome non-ATPase regulatory subunit 12 PSMD12 2.90E+01 4.18E-03
26S proteasome non-ATPase regulatory subunit 13 PSMD13 2.95E+01 3.11E-03
26S proteasome non-ATPase regulatory subunit 14 PSMD14 2.80E+01 1.85E-03
26S proteasome non-ATPase regulatory subunit 2 PSMD2 2.15E+00 4.38E-03
26S proteasome non-ATPase regulatory subunit 3 PSMD3 3.04E+01 1.48E-04
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Table 1 continued
Protein name Gene ID Log2 ratio P-value
26S proteasome non-ATPase regulatory subunit 4 PSMD4 2.79E+01 1.70E-04
26S proteasome non-ATPase regulatory subunit 6 PSMD6 2.96E+01 9.65E-03
26S proteasome non-ATPase regulatory subunit 7 PSMD7 3.75E+00 1.13E-02
26S proteasome non-ATPase regulatory subunit 8 PSMD8 2.75E+01 1.56E-03
Poly(U)-binding-splicing factor PUF60 PUF60 2.75E+01 9.95E-04
Pyrroline-5-carboxylate reductase PYCR1 2.55E+01 3.49E-03
RNA-binding protein 10 RBM10 3.30E+01 4.88E-04
RNA-binding protein 14 RBM14 2.94E+01 6.57E-03
RNA-binding protein 25 RBM25 2.75E+01 7.71E-03
RNA-binding protein 26 RBM26 2.63E+01 3.79E-02
RNA-binding protein 27 RBM27 2.70E+01 1.20E-02
RNA-binding protein 28 RBM28 2.63E+01 5.02E-03
RNA-binding motif protein, X chromosome RBMX 3.01E+01 8.90E-03
RNA 3-terminal phosphate cyclase-like protein RCL1 2.65E+01 1.64E-03
Reticulocalbin-2 RCN2 2.73E+01 2.67E-03
Replication factor C subunit 3 RFC3 2.62E+01 2.34E-02
Telomere-associated protein RIF1 RIF1 3.04E+01 9.16E-03
Serine/threonine-protein kinase RIO1 RIOK1 3.02E+01 3.05E-03
RING finger protein 219 RNF219 2.94E+01 2.50E-03
RNA-binding protein 39 RNPC2 2.86E+01 8.92E-03
60S ribosomal protein L10 RPL10 3.26E+01 7.84E-03
60S ribosomal protein L10a RPL10A 3.22E+01 2.24E-02
60S ribosomal protein L11 RPL11 3.19E+01 1.04E-03
60S ribosomal protein L12 RPL12 3.18E+01 6.43E-03
60S ribosomal protein L13 RPL13 3.30E+01 4.30E-04
60S ribosomal protein L13a RPL13A 3.17E+01 2.25E-03
60S ribosomal protein L14 RPL14 3.07E+01 7.88E-04
60S ribosomal protein L15 RPL15 5.67E+00 8.90E-03
60S ribosomal protein L17 RPL17 3.16E+01 4.69E-04
60S ribosomal protein L18 RPL18 3.28E+01 1.68E-03
60S ribosomal protein L18a RPL18A 3.24E+01 2.10E-03
Ribosomal protein L19 RPL19 3.26E+01 4.36E-03
60S ribosomal protein L21 RPL21 3.11E+01 1.99E-03
60S ribosomal protein L22 RPL22 3.05E+01 1.47E-03
60S ribosomal protein L22-like 1 RPL22L1 2.70E+01 6.60E-03
60S ribosomal protein L23 RPL23 3.09E+01 4.70E-03
60S ribosomal protein L23a RPL23A 3.24E+01 1.26E-03
60S ribosomal protein L24 RPL24 3.03E+01 1.24E-03
60S ribosomal protein L26 RPL26 3.24E+01 1.20E-03
60S ribosomal protein L27 RPL27 3.18E+01 3.06E-03
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Table 1 continued
Protein name Gene ID Log2 ratio P-value
60S ribosomal protein L27a RPL27A 3.06E+01 5.33E-04
60S ribosomal protein L28 RPL28 3.22E+01 6.23E-04
60S ribosomal protein L29 RPL29 3.19E+01 3.76E-04
60S ribosomal protein L3 RPL3 7.15E+00 6.72E-03
60S ribosomal protein L30 RPL30 3.04E+01 2.06E-03
60S ribosomal protein L31 RPL31 3.15E+01 3.12E-04
60S ribosomal protein L32 RPL32 3.18E+01 3.51E-04
60S ribosomal protein L34 RPL34 2.90E+01 4.73E-03
60S ribosomal protein L35 RPL35 3.13E+01 1.43E-02
60S ribosomal protein L35a RPL35A 3.14E+01 2.01E-02
60S ribosomal protein L36 RPL36 3.02E+01 1.49E-02
60S ribosomal protein L36a RPL36A 2.97E+01 5.51E-04
60S ribosomal protein L37a RPL37A 3.07E+01 1.05E-04
60S ribosomal protein L38 RPL38 2.90E+01 3.49E-02
60S ribosomal protein L4 RPL4 3.36E+01 1.82E-03
60S ribosomal protein L5 RPL5 3.26E+01 6.62E-03
60S ribosomal protein L6 RPL6 6.39E+00 9.35E-03
60S ribosomal protein L7 RPL7 3.33E+01 2.21E-03
60S ribosomal protein L7a RPL7A 8.22E+00 1.74E-03
60S ribosomal protein L8 RPL8 3.33E+01 9.73E-04
60S ribosomal protein L9 RPL9 3.06E+01 1.10E-04
60S acidic ribosomal protein P0 RPLP0 3.23E+01 2.18E-03
60S acidic ribosomal protein P2 RPLP2 2.87E+01 4.32E-03
40S ribosomal protein S10 RPS10 3.21E+01 1.86E-03
40S ribosomal protein S11 RPS11 3.24E+01 1.88E-03
40S ribosomal protein S12 RPS12 3.14E+01 4.05E-04
40S ribosomal protein S13 RPS13 3.22E+01 1.60E-03
40S ribosomal protein S14 RPS14 3.15E+01 4.92E-04
40S ribosomal protein S15 RPS15 3.15E+01 3.33E-02
40S ribosomal protein S15a RPS15A 3.19E+01 1.70E-03
40S ribosomal protein S16 RPS16 3.24E+01 1.08E-03
40S ribosomal protein S17 RPS17 3.19E+01 1.78E-03
40S ribosomal protein S18 RPS18 8.03E+00 7.90E-09
40S ribosomal protein S19 RPS19 3.22E+01 1.65E-03
40S ribosomal protein S2 RPS2 3.28E+01 1.71E-03
40S ribosomal protein S20 RPS20 3.21E+01 4.89E-04
40S ribosomal protein S21 RPS21 2.88E+01 2.47E-03
40S ribosomal protein S23 RPS23 3.25E+01 1.31E-03
40S ribosomal protein S24 RPS24 3.00E+01 1.10E-04
40S ribosomal protein S25 RPS25 3.14E+01 5.19E-03
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Table 1 continued
Protein name Gene ID Log2 ratio P-value
40S ribosomal protein S26 RPS26 3.08E+01 2.54E-02
40S ribosomal protein S27 RPS27 3.00E+01 3.65E-03
40S ribosomal protein S3 RPS3 3.28E+01 3.26E-03
40S ribosomal protein S3a RPS3A 3.30E+01 4.75E-04
40S ribosomal protein S4, X isoform RPS4X 6.65E+00 2.28E-03
40S ribosomal protein S6 RPS6 3.18E+01 2.28E-03
40S ribosomal protein S7 RPS7 3.28E+01 1.99E-02
40S ribosomal protein S8 RPS8 3.24E+01 3.63E-03
40S ribosomal protein S9 RPS9 3.31E+01 3.94E-03
40S ribosomal protein SA RPSA 3.32E+01 1.29E-03
Ribosome-binding protein 1 RRBP1 2.84E+01 3.20E-02
RRP12-like protein RRP12 2.58E+01 1.13E-02
Ribosomal L1 domain-containing protein 1 RSL1D1 2.69E+01 1.56E-02
U4/U6.U5 tri-snRNP-associated protein 1 SART1 2.91E+01 1.18E-04
Splicing factor, arginine/serine-rich 15 SCAF4 2.74E+01 1.68E-02
Protein SDA1 homolog SDAD1 2.64E+01 1.69E-02
Plasminogen activator inhibitor 1 RNA-binding protein SERBP1 3.28E+01 2.19E-02
Splicing factor 3B subunit 1 SF3B1 2.81E+01 8.87E-03
Splicing factor 3B subunit 3 SF3B3 2.72E+01 1.14E-02
Superkiller viralicidic activity 2-like 2 SKIV2L2 2.75E+01 8.05E-03
U5 small nuclear ribonucleoprotein 200 kDa helicase SNRNP200 3.06E+01 5.98E-03
U5 small nuclear ribonucleoprotein 40 kDa protein SNRNP40 2.72E+01 1.41E-02
Small nuclear ribonucleoprotein Sm D1 SNRPD1 3.02E+01 1.48E-03
Small nuclear ribonucleoprotein Sm D2 SNRPD2 2.92E+01 2.94E-04
Small nuclear ribonucleoprotein Sm D3 SNRPD3 2.95E+01 1.93E-02
Small nuclear ribonucleoprotein-associated proteins B and B SNRPN 3.06E+01 4.62E-04
Spectrin alpha chain, non-erythrocytic 1 SPTAN1 3.41E+01 9.63E-04
Spectrin beta chain, non-erythrocytic 1 SPTBN1 3.41E+01 9.41E-05
SRSF protein kinase 1 SRPK1 2.94E+01 5.81E-03
SRSF protein kinase 2 SRPK2 2.60E+01 2.88E-02
Serine/arginine repetitive matrix protein 1 SRRM1 2.85E+01 1.46E-02
Serrate RNA effector molecule homolog SRRT 2.57E+01 2.04E-03
Serine/arginine-rich splicing factor 1 SRSF1 2.74E+01 1.86E-04
Serine/arginine-rich splicing factor 2 SRSF2 2.69E+01 4.59E-02
Serine/arginine-rich splicing factor 3 SRSF3 2.87E+01 1.42E-03
Double-stranded RNA-binding protein Staufen homolog 1 STAU1 2.88E+01 1.18E-02
Serine/threonine-protein kinase 38 STK38 2.78E+01 2.59E-02
SUN domain-containing protein 2 SUN2 2.97E+01 6.35E-04
Heterogeneous nuclear ribonucleoprotein Q SYNCRIP 2.82E+01 1.08E-02
Very-long-chain enoyl-CoA reductase TECR 2.70E+01 4.59E-03
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In summary, all these data suggest that metformin
inhibits the MID1-dependent translation of APP and
thereby reduces Aβ plaque burden and improves cognitive
impairments in an AD mouse model.
Discussion
In this study, we show a novel regulatory mechanism
controlling the protein synthesis of APP: this mechanism
involves the MID1 protein, which induces the translation
Table 1 continued
Protein name Gene ID Log2 ratio P-value
Testis-expressed sequence 10 protein TEX10 2.64E+01 1.64E-03
THO complex subunit 2 THOC2 2.53E+01 1.37E-02
Tight junction protein ZO-2 TJP2 2.65E+01 6.69E-03
Transmembrane protein 33 TMEM33 2.74E+01 1.11E-02
Tropomodulin-3 TMOD3 2.63E+01 4.62E-03
TRMT1-like protein TRMT1L 2.82E+01 9.34E-03
Tubulin beta-3 chain TUBB3 2.57E+01 5.04E-04
Tubulin beta-4A chain TUBB4A 2.61E+01 2.90E-02
Splicing factor U2AF 35 kDa subunit U2AF1 2.90E+01 7.02E-03
Splicing factor U2AF 65 kDa subunit U2AF2 2.98E+01 4.30E-03
U2 snRNP-associated SURP motif-containing protein U2SURP 2.78E+01 1.78E-05
E3 ubiquitin-protein ligase UBR5 UBR5 2.78E+01 2.75E-02
U4/U6.U5 tri-snRNP-associated protein 2 USP39 2.88E+01 2.14E-02
Transitional endoplasmic reticulum ATPase VCP 2.80E+01 7.61E-05
Vimentin VIM 1.35E+00 2.08E-02
Methylosome protein 50 WDR77 3.30E+01 2.27E-02
Exportin-T XPOT 2.64E+01 7.27E-03
Nuclease-sensitive element-binding protein 1 YBX1 3.07E+01 3.00E-03
YTH domain-containing protein 1 YTHDC1 2.78E+01 8.82E-03
YTH domain-containing family protein 2 YTHDF2 1.60E+00 3.42E-02
Zinc finger CCCH domain-containing protein 18 ZC3H18 2.79E+01 1.14E-02
Zinc finger CCCH-type antiviral protein 1 ZC3HAV1 2.79E+01 1.27E-02
Zinc finger protein 622 ZNF622 2.75E+01 1.14E-02
Log2 ratio and p-values were calculated using measured protein intensities, i.e. eXtracted Ion Current (XIC) of all isotopic clusters associated with the identified amino
acid sequence. Log2 ratio was calculated from the intensity sum of samples/ controls. p-values are the result of a two-sided t-test, samples vs. control. In cases where
intensities had been measured in 2 (out of 3) replicates, the third intensity value was added through imputation. If no intensity could be measured in all 3 replicates,
the intensities were set from 0 to 1 in order to still be able to calculate a ratio (same applies to cases where only 1 intensity could be measured)
Fig. 3 Disruption of the MID1-complex by metformin reduces APP protein level. Primary neurons were treated with different doses of
metformin. Protein extracts were analyzed on western blots detecting APP and β-actin as loading control. Graph shows quantification of western
blots, mean values ± SEM. n = 3 *p < 0.01. APP amyloid precursor protein
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of APP by regulating mTOR-eIF signaling. Disassembly of
the MID1 protein complex by metformin reduces the
protein production of APP. Furthermore, we show that
chronic treatment of AD mice with metformin decreases
the protein level of APP and its cleavage products,
including Aβ. This together with our previous observation
that disassembly of the MID1 protein complex by met-
formin also decreases tau-phosphorylation7, makes MID1
a particularly interesting drug target for treating AD.
Among other effects, metformin induces PP2A activity
by interfering with the assembly of the MID1-PP2A-
complex7. Although MID1 has an inhibitory effect on
PP2A8, it positively regulates mTOR9. Therefore, met-
formin activates PP2A, while at the same time it sup-
presses mTOR. Decreased mTOR signalling results in
activation of autophagy and decreased translation of
mRNAs regulated by its downstream effectors S6K and
4E-BP121. The MID1 protein complex via PP2A and
mTOR stimulates translation of mRNAs that are asso-
ciated with this protein complex, some of which play a
role in neurodegeneration11–13,16.
Here we identified APP mRNA as a novel binding
partner of MID1, suggesting that the MID1 complex also
induces its translation. Since the biguanide metformin
interferes with the assembly of the MID1 protein com-
plex, it thereby reduces translation of the APP mRNA,
leading to decreased processing by the amyloidogenic
pathway. This mode of action of metformin has also been
shown for other mRNAs that are associated with the
MID1-complex, including the androgen receptor (AR)
and BACE1 mRNA14,15. Furthermore, we report a so far
unknown additional connection between MID1 and the
mTOR-dependent translation initiation pathway: MID1
binds to RPLP0, a protein of the large ribosomal subunit.
Metformin treatment interferes with the MID1-complex
assembly and thus inhibits MID1-dependent transla-
tion7,14,15. Overall, metformin seems to decrease transla-
tion of several MID1-PP2A-mTOR dependent mRNAs.
However, since chronic administration of metformin is
well tolerated in type 2 diabetes patients, this does not
seem to be particularly deleterious. Additionally, both
induction of autophagy and reduced protein translation
Fig. 4 Metformin reduces APP protein level in mice. Male and female APP/PS1 mice (age 12–13 months) were treated for 8 months with 5
g/l metformin in the drinking water. a Protein extracts from brain tissue of these animals were analyzed on western blots detecting APP and
β-actin as loading control. A representative blot of n = 3 males and n = 4 females is shown. Graphs show quantification of western blots, mean values
± SEM. * = p < 0.05. b Relative APP mRNA expression was measured in brain tissues described in a by means of real-time PCR. Columns represent
mean values ± SEM. n = 5. c Protein extracts from brain tissue of these animals was analyzed on western blots, detecting phospho-S6 (p-S6), total S6
and β-actin as loading control. A representative blot of n = 6 is shown. Graphs show quantification of western blots, mean values ± SEM. * = p < 0.05
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Fig. 5 Metformin reduces Aβ plaque burden in mice. Male and female APP/PS1 mice (age 12–13 months) were treated for 8 months with
5g/l metformin in the drinking water. a Protein extracts from brain tissue of these animals was analyzed on dot blots detecting Aβ. Representative
blots of n = 4 females and n = 3 males are shown. Graphs show quantification of dot blots, mean values ± SEM, the mean value of control animals
was set to 100%. *p < 0.05. b ELISA measurements of Aβ in brain tissues described in a. Columns represent mean values (pg/ml) ± SEM. n = 4 females,
n = 3 males. *p < 0.05. c Sagittal brain sections of mice were stained with Thioflavin-S for Aβ aggregates. Scale bar = 200 µm d Spatial learning and
memory in the Morris water maze. Mice were trained on a hidden version of the Morris water maze. After completion of training, we performed a
probe trial to test how accurately the animals had learned the location of the escape platform (target). The graph shows the number of crossings of
the target location vs. averaged crossings of corresponding positions in the adjacent, non-target quadrants (reference). Shown are means ± SEM.
n = 10 mice per group. *p < 0.05
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are especially vital for the adult nervous system, since
these processes control homeostasis of Aβ and phospho-
tau19,20. Therefore, we believe that reduced protein
translation of several mRNAs regulated by MID1/PP2A/
mTOR would be beneficial.
The use of metformin as a putative drug for treating AD
has been discussed controversially15,21–27. While in some
studies metformin treatment increased APP27 or Aβ
levels24, other studies showed that metformin attenuated
AD-like neuropathology for example by decreasing the
level of the APP processing enzyme BACE115, or
by decreasing tau hyperphosphorylation7,25. This dis-
crepancy can be explained by differences in the experi-
mental set-up in the different studies. First, the effect of
metformin seems to be dose- and time-dependent. For
example, in cell culture models high doses of metformin
(5–50mM) or long incubation times result in an increased
expression of APP and BACE124,27, while lower doses
(1–2.5 mM) decrease BACE1 protein levels as well as APP
cleavage products and tau phosphorylation7,15,23. In wild-
type mice treatment with 2 g/l metformin in the drinking
water results in increased expression of BACE1 and APP as
well as APP cleavage products24,27, while treatment with 5
g/l reduces BACE1 protein expression15 as well as tau-
phosphorylation7. Also the period of treatment seems to be
important. Different to studies in which increased APP and
BACE1 levels were detected24,27, our study lasted over a
treatment period of 8 months. Therefore, differences
between acute and chronic pharmacological treatments
could account for the observed effects. Of note, in our
experiments we detected a significant difference in Aβ
levels between female and male mice, with female mice
having an increased Aβ burden compared to male mice.
This observation is in line with previous findings, showing
that femalemice exhibit much higher γ-secretase activity in
aged brain compared to male mice and therefore, Aβ pla-
que pathology in female mouse models of AD is increased
compared to males28. Interestingly, another study in which
metformin had been used in a chronic treatment demon-
strated that learning and memory were improved by met-
formin treatment in female mice, while it had an opposite
effect in male mice26. This shows that also the sex of the
experimental animals used could account for different
findings. Another important point is the age of the
experimental animals in which the treatment was initiated.
To our knowledge our study is the first study in which
metformin treatment was initiated in aged mice displaying
an already progressed state of the disease.
Taken together, our study shows that long-term treat-
ment with metformin inhibits the MID1-dependent
translation of APP and thus reduces Aβ plaque burden
without any side effects for the animals. The administration
ofmetformin for a prolonged period (8months) started late
in life and in an already progressed state of the disease.
Therefore, our data represent the effects of metformin on
biochemical and cognitive changes of the CNS in a pro-
gressed disease stage of AD. In addition, we could
show in our previous work, that disassembly of the MID1
protein complex by metformin also decreases tau-
phosphorylation7, making the MID1 complex a particu-
larly interesting target for treating all ADneuropathologies.
Materials and methods
In vitro translation
To create an hAPP-Luciferase fusion construct, the
human APP wild type splice variant 695 cDNA sequence
was amplified by PCR from the pcDNA-hAPP695wt plas-
mid using primers APP-pGL3m-fwd and APP-pGL3m-rev
(Table 2), thereby creating HindIII and NcoI restriction
sites, which were used to insert the amplified sequence into
the pGL3m plasmid11 5′ of the firefly luciferase sequence.
To enable in vitro transcription, a T7 site was inserted by
PCR using primers T7-hAPP-ivts-fwd and pGL3–2258-
ivts-rev (Table 2). The resulting amplificate was phenol-
chloroform purified and subjected to in vitro transcription
using the RiboMAXTM Large scale RNA production
system-T7 (Promega, Mannheim, Germany) according to
the manufacturer’s instructions. In vitro transcribed RNA
was phenol-chloroform purified and translated in vitro
using the Flexi Rabbit Reticulocyte Lysate System (Pro-
mega) in presence or absence of inhibitors. Luciferase
activity was quantified using the Firefly Luciferase Assay
System (Promega) on a FLUOstar Omega 96-well plate
reader (BMG Labtech, Ortenberg, Germany).
Immunoprecipitation
Cells have been authenticated by PCR-single-locus-
technology (service by Eurofins (Ebersberg, Germany)) in
December 2016. HEK293T cells were transfected with
Fig. 6 Metformin treatment does not induce degradation of Aβ.
Determination of cellular Aβ42 aggregate loads in SH-EP cells
containing TAMRA-Aβ42 aggregates. Cells were treated with different
amounts of metformin and Aβ42 aggregate load was quantified by
automated fluorescence microscopy. Aggregates per cell were either
quantified by the TAMRA-labeling or alternatively by
immunofluorescence using the 6E10-Aβ-antibody. ECGC, a substance
that was previously reported to remodel Aβ fibrils32, 33, was used as
positive control. Graph show mean values ± SEM. n = 3. *p < 0.001
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pCMV-MID1-Tag2A using PolyFect (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Untransfected cells were used as control. Cell pellets were
lysed in TKM buffer (20 mM Tris pH 7.4, 100 mM KCl, 5
mM MgCl2, 0.5% NP40, 1 mM DTT, protease inhibitors)
using a Precellys cell homogenizer. For pre-clearing, 200
µl of IgG-agarose beads were added to the lysates and
incubated rotating for 30min at 4 °C. The beads were
pelleted for 5 min at 21,000 x g. Precleared lysates were
then added to 200 µl anti-FLAG M1 Agarose Affinity Gel
(Sigma-Aldrich/Merck, Darmstadt, Germany). After
overnight rotation at 4 °C, the beads were washed 6 times
and resuspended in 50 µl 1x SDS Buffer and boiled for 10
min at 95 °C. The proteins were then either identfied by
mass spectrometry analysis or analyzed on a western blot.
For ribosome disassembly, immunoprecipitation was
performed in TKM buffer containing 40mM EDTA. For
RNase digest, the beads were washed three times after
overnight incubation, anti-FLAG beads were split into
two aliquots and resuspended in NEBuffer 3 (B7003S,
New England Biolabs, Frankfurt, Germany). RNase If
(M0243, New England Biolabs) was added to a final
concentration of 500 U/ml to one immunoprecipitate and
incubated for 45 min at 37 °C. Subsequently, beads were
washed three times and treated as described above.
Mass spectrometry
The eluted proteins were concentrated into one band
on an SDS-PAGE gel. The band was excised and the
proteins contained were processed using an automated
sample preparation setup29. The generated peptides were
purified on StageTips30. Samples were measured on a Q-
Exactive mass spectrometer (Thermo-Fisher, Waltham,
MA, USA) coupled to a Proxeon nano-LC system
(Thermo-Fisher) in data-dependent acquisition mode,
selecting the top 10 peaks for HCD fragmentation. A 1h
gradient (solvent A: 5% acetonitrile, 0.1% formic acid;
solvent B: 80% acetonitrile, 0.1% formic acid) was applied
for the samples using an in-house prepared nano-LC
column (0.075mM× 150 mM, 3 μm Reprosil C18, Dr.
Maisch GmbH, Ammerbuch-Entringen, Germany). A
volume of 2 μl sample was injected and peptides were
eluted with 3 h gradients of 5–75% solvent B at flow rates
of 0.25 μl/min. MS acquisition was performed at a reso-
lution of 70,000 in the scan range from 300 to 1700 m/z.
The normalized collision energy was set to 26 eV. The
mass window for precursor ion selection was set to 2.0 m/
z. The recorded spectra were analyzed using the Max-
Quant software package (Version 1.3.0.5)31 by matching
the data to the Uniprot human database (downloaded on
06.05.2012) with a false discovery rate (FDR) of 1%.
Peptide treatments
Murine primary cortical neurons were treated with 2.5
µM of a peptide that mimics the MID1-α4 binding site and
thus outcompetes MID1 from binding to α4-PP2Ac. As
control a mutant peptide was used. Peptides (GSK’364A
and GSK’365A) containing a 29-residue sequence from α4
(AQAKVFGAGYPSLPTMTVSDWYEQHRKYG and
AQAKVFGAGYPSLPTMTVSDWAEQHRKYG, respec-
tively) with an N-terminal sequence derived from HIV-
TAT protein (RKKRRQRRR) were supplied by Cambridge
Research Biochemicals (Billingham, UK). They were syn-
thesized using standard automated solid-phase peptide
synthesis via the Fmoc/tBu strategy. Cleavage from the
resin was performed using 95% trifluoroacetic acid. Crudes
were purified by preparative high-performance liquid
chromatography (HPLC), freeze dried and characterized by
high-performance liquid chromatography (HPLC) and
matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry.
In vivo treatments mice
Male and female APP/PS1 (B6C3-Tg(APPswe,PSEN1dE9)
85Dbo/Mmjax) mice (age 12–13 months) were treated for
8 months with 5 g/l metformin in the drinking water with
daily change of water and addition of fresh metformin.Water
intake and body weight of the animals were monitored. After
8 months of treatment, animals were sacrificed and brains
were snap-frozen in liquid nitrogen and broken up using a
Table 2 Primer sequences
mAPP-RT-fwd CAC ATC GTG ATT CCT TAC CG
mAPP-RT-rev GTC TCA CAA ACA TCC ATC CG
mGAPDH-RT-fwd GCA CAG TCA AGG CCG AGA AT
mGAPDH-RT-rev GCC TTC TCC ATG GTG GTG AA
APP-pGL3m-fwd TGC AAA AAG CTT GGC ATT CCG GTA CTG TTG GTA AAG CCA
APP-pGL3m-rev CGT CTT CCA TGG CGC CTG GAC CGT TCT GCA TCT GCT CAA AGA ACT TGT AGG T
T7-hAPP-ivts-fwd CGA AAT TAA TAC GAC TCA CTA TAG GGG TAA AGC CAC CAT GCT GCC CGG TTT GGC ACT GC
pGL3-2258-ivts-rev CCG CGC CCA CCG GAA GGA GCT GAC TGG
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mortar. All procedures were in compliance with German
Animal Protection Law and were approved by the competent
authorities (Landesamt für Naturschutz und Ver-
braucherschutz Nordrhein-Westphalen; AZ 87–51.04.2011.
A049/01).
Morris water maze
We assessed spatial learning and memory in the Morris
water maze in APP/PS1 mice treated with metformin or
vehicle control. The water pool (Med Associates) had a
diameter of 1.2 m and was filled with opaque water
(temperature: 24 °C). Mice received 6 daily training trials
for 3 consecutive days on a hidden version of the Morris
water maze (i.e., the maze contained an escape platform
hidden underneath the water surface in a constant loca-
tion of the pool). To evaluate the accuracy with which the
animals had learned the position of the escape platform,
we performed a probe trial (during which the platform
was removed from the pool) once training was completed.
Behavior of the animals was recorded using an automated
tracking system (Ethovision XT, Noldus). We determined
the number of crossings of the exact target location (i.e.,
where the platform was located during training) and
compared it to the average crossings of analogous posi-
tions in the adjacent, non-target quadrants (reference).
Thioflavin-S staining
Sagittal brain sections were incubated in 1x TBS buffer
containing 10% Triton X-100 and transferred onto glass
slides. The slides were dried overnight at room temperature.
Slides were washed 3 times for 3min in distilled water, and
incubated for 3min in 0.1% Thioflavin-S staining solution
(dissolved in 10% ethanol diluted in distilled water) in the
dark. Sections were washed 3 times in distilled water and
incubated for 20min in 1% acetic acid in the dark. Slides
were washed with tap water, cover-slipped with mounting
medium (Thermo-Fisher), and stored in the dark at 4 °C.
Western blot
Brain samples were homogenized either in RIPA buffer
(20 mM Tris-HCl (pH 7.5), 150mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5
mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1
mM Na3VO4, 1 μg/ml leupeptin) or in SDS PAGE buffer
B (40 mM Tris-HCl pH 6.8, 4% Glycerol, 2% SDS, 0.01%
bromophenolblue, 2 mM 2-mercaptoethanol), sonicated
and boiled for 5 min at 95 °C. Proteins were analyzed on
10 or 12% SDS gels and blotted onto PVDF membranes
(Roche, Mannheim, Germany). Blots were blocked in milk
and incubated with the antibodies listed below.
Bands were densitometrically quantified using AIDA
software v4.27 (Raytest, Straubenhardt, Germany).
Statistical analysis
Statistical analyses were performed using two-way
ANOVA, as well as Student’s t-test or Mann-Whitney test
(two-tailed) for two-group comparisons, as appropriate.
Dot blot
Brain samples were homogenized in RIPA buffer. 50 µg
total protein per well were loaded and proteins were
transferred to a PVDF membrane using a HYBRI-DOT
manifold. The aggregates on the membrane were detected
by incubation with anti-beta-amyloid 6E10 antibodies
(BioLegend, San Diego, CA, USA).
ELISA
ELISA assays to measure Aβ were performed using the
Aβ40 / Aβ42 ELISA Kits (Life Technologies) according to
the manufacturer’s protocol.
Antibodies
The following antibodies were purchased from Cell
Signaling (Leiden, Netherlands): S6 (#2317), pS6 (#4858),
actin (#4967), eIF3A (#3411), eIF4G (#2498), RPL5
(#51345) and GAPDH (#2118). FLAG-HRP (A8592)
antibody was purchased from Sigma; RPLP0 (ab192866),
RPS3 (#128995), and APP (ab2071) from Abcam (Cam-
bridge, UK), and anti-beta-amyloid 6E10 from BioLegend
(803001).
Real-time PCR
Total RNA was isolated using the RNeasy Plus Mini Kit
(Qiagen). cDNA was synthesized using the TaqMan
reverse transcription reagents kit (Applied Biosystems,
Waltham, MA, USA) and real-time PCR was carried out
using the SYBRGreen PCR master mix (Applied Biosys-
tems). Primers used are listed in Table 2.
RNA immunoprecipitation
Murine primary cortical neurons were transfected with
FLAG-tagged MID1 using Lipofectamine 2000 (Invitro-
gen Waltham, MA, USA). 48 h after transfection, cells
were treated with or without 2.5 mM metformin and
incubated another 24 h. After UV-crosslinking (200 mJ/
cm2) cells were lysed in TKM buffer (20 mM Tris pH 7.4,
100mM KCl, 5 mM MgCl2, Complete protease inhibitor
cocktail (Roche), RNAse inhibitor, 0.2% NP40) and
MID1 protein complexes were purified by immunopre-
cipitation using anti-FLAG M1 Agarose Affinity Gel
(Sigma-Aldrich) or IgG-agarose (Sigma-Aldrich) as
a negative control. Protein-bound mRNA was isolated
after DNAse and proteinase K digestion by phenol-
chloroform purification and analyzed by RT-PCR. Primers
used are listed in Table 2.
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Automated fluorescence microscopy and determination of
cellular Aβ42 aggregate loads
For fluorescent labeling of Aβ aggregates, 20 µM Aβ42
peptide stock solutions diluted in low salt buffer (10mM
NaCl, 1.9 KH2PO4, 8.1mM K2HPO4, pH 7.4) were mixed
with5%Aβ42peptideswhichhavebeenN-terminally labeled
with the fluorophore 5-Carboxytetramethylrhodamine
(TAMRA) in solid-state peptide synthesis by AnsSpec, Fre-
mont, USA. Then, mixed Aβ peptide solutions were aggre-
gated at 37 °C for 18 h under 300 rpm constant agitation
followed by sonication with a Sonic Dismembrator Model
120 from Fisher Scientific GmbH (Schwerte, Germany) at
low intensity for 6 rounds of 10 s. SH-EP cells (DSMZ,
Braunschweig,Germany)were cultured inDMEM(Gibcoby
Thermo-Fisher GmbH, Dreeich, Germany) containing 10%
fetal bovine serum(FBS), 5%Glucose, 100units/ml penicillin
and streptomycin, respectively. Incubationwas carried out at
37 °Cwith 5% (v/v) CO2. For Aβ42 aggregate internalization,
cellswere treatedwith 600nMor1 µMTAMRA-Aβ42 for 18
h. To ensure removal of free and surface-bound aggregates,
Aβ containingmediumwas aspirated, cellswerewashedwith
phosphate-buffered saline (PBS), trypsinized andcollected in
fresh medium. Then, cells were seeded into 96-well cell
culture plates and treated with different amounts of met-
formin for 6 h. Cells were fixed in 2% paraformaldehyde for
20min at room temperature, followed by Nuclei staining
with Hoechst (1:2500 Hoechst 33342, Sigma-Aldrich Che-
mie Gmbh Munich, Germany) and then washed twice with
PBS, before fluorescent microscopy was performed in a
Cellomics ArrayScan Hight-Content System (Thermo-
Fisher) using an objective with 20-fold magnification. After
image acquisition, automated data analysis was performed
using ArrayScan VTI (700 Series, Thermo-Fisher). For
quantification, individual cells were detected via Hoechst
fluorescent signals (XT53, filter and dichroic-emitter pair)
and total TAMRA fluorescent areas per cell (XT32, filter and
dichroic-emitter pair) were measured and calculated from
technical triplicates. Alternatively, Aβ was stained by
immunofluorescence using the 6E10 antibody (BioLegend).
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